Clinical trial · Observational
International Extranodal NK/T-cell Lymphoma Project
International Extranodal NK/T-cell Lymphoma Project: Prognostic Factors in the Era of Nonanthracycline-based Treatment
NCT02386813CI-TRIAL-00026901PINKcompletedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study is to explore risk factors for poor progression-free survival (PFS) and overall survival (OS) in ENKTL, and establish a prognostic model for ENKTL patients treated with non-anthracycline based treatment.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Extranodal NK/T-cell Lymphoma, Nasal Type | Extranodal NK-/T-Cell Lymphoma, Nasal Type | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (2)
- label
- Training cohort
- description
- 1. Patients diagnosed with ENKTL, nasal type between January 1, 1995 and December 31, 2013; 2. Patients treated with non-anthracycline based therapy as an initial treatment.
- label
- Validation cohort
- description
- 1. Patients diagnosed with ENKTL, nasal type between January 1, 1998 and December 31, 2014; 2. Patients treated with non-anthracycline based therapy as an initial treatment.
Primary outcomes (1)
- measure
- Overall survival
- timeFrame
- 5 year
- description
- Time between the date of diagnosis and any kinds of death
Secondary outcomes (1)
- measure
- Progression-free survival
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- All
Show eligibility criteria text
Inclusion Criteria: * Patients diagnosed with ENKTL, nasal type * Patients diagnosed between January 1, 1995 and December 31, 2014 * Patients treated with nonanthracycline-based therapy as the initial treatment after diagnosis * Nonanthracycline-based therapy includes the following treatments: * Radiotherapy including concurrent chemoradiation * Chemotherapy not including anthracycline such as doxorubicin (e.g. SMILE, VIPD) The type of salvage treatment will not be a criterion for exclusion. Thus, patients who had received various kinds of salvage treatment including anthracycline-containing regimens can be included. Patients who had undergone autologous or allogeneic stem cell transplantation can also be included in the analysis if they satisfy the above-mentioned inclusion criteria. Exclusion Criteria: * Patients who had received anthracycline-based therapy, such as CHOP or CHOP-like regimens, as the initial treatment. * Patients who do not have pathology slides available for central review.
References
Publications (0)
Data not yet available
No reference posted for this study.